Obracin (Tobramycin)

Tobramycin binds to the 30S subunit of bacterial ribosomes, causing misreading of messenger RNA and halting protein synthesis. This leads to rapid bacterial cell death, especially in aerobic Gram‑negative organisms such as Pseudomonas, Escherichia coli, and Klebsiella species.

The dosing regimen for Obracin is individualized. A qualified prescriber determines the dose, frequency, and duration based on the infection type, patient weight, renal function, and severity of illness. No fixed dose can be provided without a medical prescription.

Data on tobramycin use during pregnancy and lactation are limited. The drug crosses the placenta and may affect the fetus, and it can be secreted in breast milk. Use is reserved for situations where the potential benefit outweighs the possible risk to the mother and child.

To place an order, submit an enquiry on the Obracin product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Obracin (tobramycin) belongs to the aminoglycoside class, similar to gentamicin and amikacin. Compared with gentamicin, tobramycin often shows greater activity against Pseudomonas aeruginosa but shares similar risks of nephrotoxicity and ototoxicity. Choice between agents depends on local susceptibility patterns, patient renal function, and clinician preference.

Obracin should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Do not freeze the product. Before use, inspect the vial for particulate matter or discoloration and discard if any abnormalities are observed.

Obracin is supplied as a sterile injectable solution for intravenous or intramuscular injection. Administration is performed by a qualified healthcare professional using aseptic technique. The infusion rate and volume are determined by the prescriber, and the drug may be given as a bolus or diluted in compatible IV fluids.

The most serious adverse effects of tobramycin include irreversible ototoxicity (permanent hearing loss or balance impairment) and severe nephrotoxicity leading to acute kidney injury. Neuromuscular blockade causing respiratory muscle weakness can also occur, especially when combined with other neuromuscular blocking agents.

Obracin is contraindicated in patients with a known hypersensitivity to tobramycin or any aminoglycoside. It should be used with extreme caution, or avoided, in individuals with pre‑existing severe renal impairment, significant hearing loss, or those receiving other nephrotoxic or ototoxic medications.